GlassScriptPhysician profile
Aubrey Ford
NPI 1952015273
$1,646.18
in general payments reported to CMS, 2019-2025
22 companies · $708 in 2025
The $708 reported for 2025 was more than what 81% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $511 · 2024: $427 · 2025: $708.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,646.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,646.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $518.50 | 2023-2025 | |
| Lilly USA, LLC | $227.39 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $156.25 | 2023-2025 | Wegovy, Ozempic, Rybelsus |
| Glaxosmithkline, LLC. | $99.51 | 2023-2025 | Shingrix, Arexvy |
| Janssen Pharmaceuticals, INC | $81.60 | 2023-2024 | Spravato |
| Astrazeneca Pharmaceuticals LP | $68.50 | 2025 | Airsupra |
| Amgen INC. | $62.30 | 2024-2025 | Repatha, Otezla, Krystexxa |
| Organon LLC | $57.83 | 2023-2025 | Nexplanon |
| Neurocrine Biosciences, INC. | $40.84 | 2025 | |
| Boston Scientific Corporation | $40.82 | 2024 | Wavewriter Alpha Prime 16 |
| Sanofi-Aventis U.S. LLC | $40.38 | 2024-2025 | |
| Pfizer INC. | $38.08 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $32.53 | 2025 | Jardiance |
| Biomerieux INC | $28.00 | 2025 | Biofire Spotfire Control Station |
| Grifols USA, LLC | $23.20 | 2024 | Prolastin-C Liquid |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corcept Therapeutics | $22.14 | 2025 | Korlym |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $20.06 | 2025 | Xifaxan |
| Cranial Technologies, INC | $19.50 | 2023 | Doc Band |
| Edwards Lifesciences Corporation | $18.30 | 2023 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Dynavax Technologies Corporation | $18.13 | 2023 | Heplisav-B |
| Currax Pharmaceuticals LLC | $17.35 | 2023 | Contrave |
| Sanofi Pasteur INC. | $14.97 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aubrey Ford listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.